Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 980-994
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.980
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.980
Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression
Motomichi Fujita, Fumio Fukai, Department of Molecular Patho-Physiology, Tokyo University of Science, Noda 278-8510, Chiba, Japan
Hideo Suzuki, Department of Gastroenterology, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan
Author contributions: All authors contributed equally to the conception of this study, drafting, critical revision, and editing of the manuscript, and final approval of the submission.
Conflict-of-interest statement: The authors declare no conflicts of interests in regards to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fumio Fukai, PhD, Professor, Department of Molecular Patho-Physiology, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Chiba, Japan. fukai@rs.noda.tus.ac.jp
Received: February 21, 2021
Peer-review started: February 21, 2021
First decision: May 8, 2021
Revised: June 3, 2021
Accepted: August 11, 2021
Article in press: August 11, 2021
Published online: September 15, 2021
Processing time: 201 Days and 3.2 Hours
Peer-review started: February 21, 2021
First decision: May 8, 2021
Revised: June 3, 2021
Accepted: August 11, 2021
Article in press: August 11, 2021
Published online: September 15, 2021
Processing time: 201 Days and 3.2 Hours
Core Tip
Core Tip: Exposure of the cryptic functional site TNIIIA2 from the Tenascin-C (TNC) molecule and its potent and sustained activation of beta1-integrins appear to be associated with the development of colon cancer and its malignant progression. Inhibition of the biological function of TNIIIA2 derived from TNC molecule may be a promising strategy for the prevention and treatment of colon cancer.